Mike Doustdar, CEO of Novo Nordisk (NYSE:NVO), voiced concerns on Friday about how President Donald Trump’s decision to introduce 100% tariffs on imported branded pharmaceuticals fits within the framework of trade agreements between the European Union and the United States.
Doustdar said the connection between the latest U.S. tariff measures and the EU-US deal has yet to be clarified. “It is not yet clear how today’s announcement on U.S. tariffs relates to the EU/US trade agreement,” he remarked.
The executive stressed that Novo Nordisk is willing to work with U.S. officials to ensure future trade and healthcare policies foster innovation, maintain investment flows, and secure patient access to treatments across both regions.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.